Diagnosis and management of hematopoietic cell transplant-associated thrombotic microangiopathy (TA-TMA) are very complex and controversial, given multiple ongoing issues and comorbidities in sick ...
After re-examination, the CHMP confirmed its negative opinion of Yartemlea for HSCT-associated TMA, citing insufficient ...
A 37-year-old man walked into a hospital in China with black, tarry stools and blood pressure so high it threatened to shear ...
Researchers discover a link between an increase in protein Ba of the complement immune system and the eventual development of thrombotic microangiopathy in patients who have received an allogeneic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Due to increasing demand for YARTEMLEA drug supply in the U.S. commercial market, Omeros has informed CHMP of its intention to terminate the YARTEMLEA compassionate-use program. Compassionate-use ...
SEATTLE, September 02, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)-- Omeros ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results